ABSTRACT: The presence of neurofibrillary tangles in the brain is a hallmark feature of several neurodegenerative diseases termed "tauopathies," including Alzheimer's disease (AD) and the tau molecular subgroup of frontotemporal lobar degeneration (FTLD-tau C]PBB3-have been described and are considered promising as potential tau radioligands. Tau imaging agents offer the opportunity of in vivo topographical mapping and quantification of tau aggregates in parallel with clinical and cognitive assessments. As such, tau imaging is considered of key importance for progress toward earlier and more accurate diagnosis of tauopathies as well as for the monitoring of therapeutic interventions and drug development. Here, we shed light on the most important developments in tau radiopharmaceuticals, highlighting challenges, possibilities and future directions.
INTRODUCTION
Tau is a phosphoprotein that belongs to the microtubule-associated family (MAP). In the human brain, tau proteins can assume six different isoforms, with each variant containing a microtubule-binding domain comprising three repeat (3R) or four repeat (4R) regions in the protein carboxy-terminal (C-terminal) as well as one or two amino acid terminal (N-terminal) inserts. 1 Importantly, the expression of tau isoforms may not be equal across neurons. For instance, tau messenger RNAs containing exon 10-which encodes the fourth microtubule-binding domain-are not found in granular cells within the dentate gyrus. 2 As such, tau isoforms are thought to be differentially distributed within neuronal subpopulations.
A key mediator of microtubule assembly and stability, [3] [4] [5] tau functionality is regulated by a wide range of serine and threonine phosphorylation sites. In addition to reducing tau's affinity for microtubules, abnormal phosphorylation of these sites results in a complementary toxic gain of function-in the form of an increased propensity for misfolding and subsequent polymerization-with this mechanism believed to occupy a central role in various neurodegenerative conditions, 6 ,7 including Alzheimer's disease (AD), and the tau molecular subgroup of frontotemporal lobar degeneration (FLTD-tau) ( Table 1 ). In the case of AD, the accumulation of abnormally phosphorylated tau is known to proceed hierarchically-affecting first the transentorhinal pre-α layer (Braak stage I-II), before progressing toward limbic (Braak stage III/IV) and isocortical areas (Braak stage V/VI)-with its spread thought to occur following a shift toward prion-like self-propagation. 8, 9 Though quantitative assessment of cerebrospinal fluid (CSF) levels of tau and phosphorylated tau (p-tau) are currently acknowledged as biomarkers of neurodegeneration, 10 with levels shown to correlate with cognitive impairment in AD, [11] [12] [13] the collection of CSF via lumbar puncture is invasive in nature and is associated with high inter-laboratory variability, hampering comparison of data across centers. 14 In addition, levels of tau and p-tau are unable to provide information regarding the topography of tau pathology in the brain, which is critical to the differential diagnosis of certain tauopathies. 15, 16 The concept of misfolded tau as a central process underlying neurodegeneration [17] [18] [19] [20] has led to the development of tau-focused therapeutics aiming to reduce tau-mediated neurodegeneration, with approaches including microtubule stabilizing agents, reduction of tau hyperphosphorylation, inhibition of tau fibril aggregation, and promotion of microtubule stability. 21 As such, the development of noninvasive methodologies has a high priority for determining tau pathology propagation and monitoring treatment effects in clinical trials.
Positron emission tomography (PET), a noninvasive molecular imaging method, allows for quantitative analysis of a wide array of biological processes in the living human brain. Recently, three new classes of radiopharmaceuticals with a high affinity for tau tangles have been described (Table 2) . PET using tau radiopharmaceuticals holds the promise of accurate, reliable, and reproducible quantification of both regional and global tau burden, which could translate into earlier and more accurate differential diagnosis, as well as aid in monitoring disease progression and therapeutic efficacy in clinical trials.
In a recent review, we underscored the opportunity for improved modeling using tau radiopharmaceuticals and animals models. 26 Here, we shed light on the most promising tau radiopharmaceuticals and highlight future directions for tracking tau pathology using PET molecular imaging.
TAU RADIOPHARMACEUTICALS
Until recently, the main focus of PET molecular imaging has been the development of highly specific ligands for early detection of amyloid deposition. 29 In fact, low levels of tau aggregates in the brain (relative to β-amyloid), as well as the multiple structural conformations it can assume, make tau tracking a more complicated task when compared with detection of β-amyloid deposition. 30 Recently, three new classes of compounds have been developed aiming to bind tau fibrils and stand as potential tau imaging biomarkers. These include: (1) quinoline derivatives, (2) benzimidazole pyrimidine derivatives, and (3) benzothiazole derivatives. 15, 23, 25 In the following paragraphs, we describe the most important insights generated from in vitro and in vivo studies using these novel tracers (for detailed information, see Table 3 ).
Quinoline Derivatives
The first quinoline derived tau ligand was [ ]THK523 bound to tau aggregates in AD hippocampal sections and not to amyloid pathology confirmed using anti-β-amyloid and anti-tau antibodies. 15 Furthermore, [
18 F]THK523 was found to accumulate in Sommer's sector (CA1) as well in layers pre-and pri-α of the entorhinal cortex in AD brain sections. These findings were consistent with the density of PHF-tau deposition, as confirmed via immunohistochemistry. 31 However, a recent autoradiography study showed that [ 18 F]THK523 has affinity only for tau filaments present in AD brains, but not for tau lesions present in non-AD tauopathies. 36 Immunostaining with fluorescent THK5105 and THK5117 indicated colocalization with tau (AT8 antibody) in human hippocampal brain sections. 22 In addition, autoradiography using [ 18 F]THK5117 showed strong accumulation in regions displaying high amounts of tau deposition, such as the subiculum, parahippocampus, CA1 subfield, insula, inferior and middle temporal gyri, and the cingulate gyrus. 22 Importantly, in vitro validation using binding assays and autoradiography combined with immunohistochemistry is sine qua non for the development of novel radiopharmaceuticals. In fact, these parameters are used to define which radiopharmaceuticals should be further investigated in in vivo studies.
In vivo studies showed that [ F]T808 tracers showed fast brain uptake followed by a rapid washout in normal mice, suggesting low nonspecific binding. 23, 24 However, [ 18 F]T807 was insensitive to differences between APPswe-Tau and wild-type background mice. 15 The first [ 18 F]T807 PET imaging results obtained in healthy controls (HCs), mild cognitive impairment (MCI), and AD subjects showed favourable kinetics-with both rapid brain delivery and WM clearance-as well as low nonspecific WM and cortical binding in HCs. In patients with MCI and AD, a distinct pattern of tracer uptake was observed, relative to the cerebellum-comprising lateral temporal, mesial temporal, parietal, occipital, and frontal cortices-mirroring the current understanding of tau deposition, as described by Braak and Braak. 32 Similar findings were obtained using [
18 F]T808, with increasing signal intensity within these regions noted as a function of clinical severity. Although difficult to determine because of the small sample size, these results suggest that a 30-to 50-minute imaging time point may prove sufficient with respect to differentiating HCs from subjects with AD, with a time frame of 80 to 100 minutes optimal for detection of smaller amounts of tau deposits. 37 Benzothiazole Derivative: [
C]PBB3
Following a screening of several fluorescent chemicals with affinity for β-sheet conformations, a PBB class of ligands was 
SUMMARY OF GENERAL PROPERTIES OF TAU RADIOPHARMACEUTICALS
The association between autoradiographic and immunohistochemical findings across multiple brain regions in both human and transgenic mouse brain tissue revealed the colocalization of all tracers with immunoreactive tau antibodies, indicating high selectivity for tau aggregates. Furthermore, autoradiography studies have provided specific and nonspecific binding, number of available binding sites, and affinity, parameters crucial for the interpretation of PET studies (for review, see (39); Table 2 ). Additionally, the tau tracers here reviewed possess desirable properties for consideration as potential neuroimaging probes, including high lipophilicity, low molecular weight, high selectivity/ affinity, and rapid plasma clearance.
39,40

Possibilities and Challenges for in vivo Tracking of Tau Pathology
Clinical PET using such tau radiopharmaceuticals should be viewed as a work in progress. Initial PET studies using [ Based on these early clinical studies, tau tracers may facilitate the differential diagnosis of AD-where tau tangles are composed of equimolar 3R and 4R isoforms 41 -and non-AD tauopathies, where tau tangles contain predominantly 3R or 4R isoforms. When combined with complementary structural and functional imaging approaches, the use of tau tracers may allow for improved detection and characterization of mixed pathology and refine our current understanding of the link between tau deposition, metabolic change, and brain atrophy. At the same time, tau tracers may provide further insight into the link between alterations in tau protein distribution that accompany normal aging and performance decrements on neuropsychological measures in nondemented elderly individuals. 42 In the context of clinical trials involving tau-directed therapeutics, tau PET ligands may serve as diagnostic biomarkers to guide population enrichment strategies, to calculate sample size, and to increase the statistical power via population stratification or through use as baseline predictors. 43 In parallel, tau-ligands can serve as endpoint biomarkers to monitor the rate of disease progression as well as response to therapy. Finally, tau ligands may aid in the testing of new hypotheses, including the hypothesis that β-amyloid and tau pathology arise independently in sporadic AD, with incident β-amyloid pathophysiology interacting synergistically with an antecedent limbic/ brainstem tauopathy. 10, 44 Despite the promise held by the tracers discussed here, a number of challenges remain. Given that structural polymorphisms are the rule rather than the exception, 45 with a given tau isoform assuming various conformations, and different isoforms assuming similar forms ultrastructurally, 46 the distribution of such tau aggregates within the brain varies by phenotype. 45 Though an advantage in terms of differential diagnosis, the underlying assumption-namely, that binding of tau ligands will be comparable across the spectrum of tau polymorphisms-is unlikely. 45 In addition, the ability of tracers to bind tau may be affected by different posttranslational modifications 47 such that a given radiotracer may be able to bind PHF-tau but not other ultrastructural tau conformations, such as straight filaments or randomly coiled filaments. Additionally, tau deposition from normal aging must be addressed to provide a reliable threshold and avoid false positives given the presence of tau pathology in a certain percentage of cognitively normal individuals. 48, 49 Finally, additional PET studies incorporating increased subject numbers and a wider range of tauopathies are necessary to further validate the use of tau ligands in clinical settings.
CONCLUSION
The growing interest in tau radiopharmaceutical will surely contribute to significant advancements in the field. Indeed, it is expected that many additional tau-focused radiopharmaceuticals will soon be examined. Current tau tracers hold translational value in terms of characterizing the link between the progression of tau pathology and cognitive impairment as well as in terms of monitoring treatment effects in clinical trials using tau-focused therapeutics. Finally, tau tracers hold the potential for inclusion as biomarkers of neurodegeneration, to be used alone or in parallel with CSF tau measurements in order to achieve an improved understanding of tauopathies.
